Greiner Bio-One and SCIENIONGreiner Bio-One is a global leader in fields of diagnostics, biotechnology, medical devices and in vitro diagnostics. The company recently announced that it entered into an agreement with SCIENION AG to develop more integrated rapid diagnostic tests. SCIENION AG is a leading provider of ultra-low volume precision liquid handling systems.

Rapid diagnostic tests (RDTs) are intended to provide results conveniently and immediately to the patient while still at the health care facility or screening site. Diagnosis at the point of care reduces the need for multiple visits to receive results and also improves specificity of diagnosis, resulting in faster treatment. Rapid tests are used in a variety of point-of care-settings-from homes to primary care clinics or emergency rooms—and many require little to no laboratory equipment or medical training.

The collaboration between Greiner Bio-One and SCIENION will focus on the development of new rapid diagnostic tests that will optimize patient care by providing sensitive and accurate test results within only 75 minutes. It will bring together Greiner Bio-One’s innovative Genspeed® testing system and SCIENION’s core competencies in ultra-low volume liquid dispensing, assay miniaturization and microarray manufacturing.

Greiner Bio-One’s Genspeed® platform can quickly identify genetic materials of bacteria and viruses in a specimen via the rapid analysis of the corresponding nucleic acids. Their GENSPEED® MRSA application can provide accurate and rapid detection of methicillin-resistant Staphylococcus aureus (MRSA) within 75 minutes.

SCIENION AG’s sciFLEXARRAYER product line is the perfect tool for automated ultra-low volume liquid handling of various types of samples (i.e. biological, organic, nanoparticle and dyes) in diagnostics, genomics, proteomics and technical applications.

It is expected that combining SCIENION AG’s expertise and sciFLEXARRAYER technology with Greiner Bio-One’s Genspeed® platform will optimize treatment outcomes for patients.

Dr. Max Sonnleitner, Head of Rapid Testing Technologies/ Business Development at Greiner Bio-One Diagnostics said, “We are looking forward to this collaboration to address the significant market need in the detection of human pathogens utilizing our Genspeed® platform. Similar to our Genspeed® MRSA testing system, all jointly developed future tests have the potential to become very successful on the market”.